The re-emergence of therapeutic uses for mind-altering, psychedelic drugs has brought the field of mental health to a new frontier in research, practice, and policymaking. In the past two decades dozens of clinical trials investigating therapeutic applications of psychedelics—including MDMA, psilocybin, and ketamine—have shown promising results in the treatment of trauma-related disorders, some forms of anxiety, and depression. These substances have also garnered preliminary support from the Food and Drug Administration, which has fast-tracked their development. As the field of psychedelic science continues to grow, a serious consideration of these novel treatments in the context of social work practice and values is imperative. This paper offers a brief overview of MDMA-, psilocybin-, and ketamine-assisted treatments, and presents an initial discussion of questions pertinent to social work practice raised by their use, including: safety, efficacy, theory of change, training needs, and social justice considerations.

改变思维的迷幻药物治疗用途的重新出现，将心理健康领域带到了研究、实践和决策的新前沿。在过去的二十年里，数十项研究迷幻药（包括摇头丸、裸盖菇素和氯胺酮）治疗应用的临床试验在治疗创伤相关疾病、某些形式的焦虑和抑郁方面显示出有希望的结果。这些物质还获得了食品和药物管理局的初步支持，并加快了它们的发展。随着迷幻科学领域的不断发展，在社会工作实践和价值观的背景下认真考虑这些新疗法势在必行。本文简要概述了摇头丸、裸盖菇素和氯胺酮辅助治疗，